22157.jpg
Ceftriaxone Industry Research 2024: Effective Treatment of Multi-Drug Resistant Infections Bolsters Growth - Global Forecasts to 2032
June 28, 2024 11:31 ET | Research and Markets
Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Global Ceftriaxone Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
Transparency Market Research
Ceftriaxone Market Size Worth USD 2.2 billion by 2031, Expanding at a CAGR of 2.9% | Exclusive Report by Transparency Market Research
August 18, 2023 08:30 ET | Transparency Market Research
Wilmington, Delaware, United States, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global ceftriaxone market is projected to flourish at a CAGR of 2.9% from 2022 to 2031....
Rafarma Pharmaceuticals, Inc. logo
Rafarma Pharmaceuticals (RAFA) Commences Preparation of Audited Financials
May 12, 2014 09:15 ET | Rafarma Pharmaceuticals, Inc.
MOSCOW, May 12, 2014 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (Pink Sheets:RAFA) has commenced a formal audit to provide additional transparency in its public filings with a forward view to...
Rafarma Pharmaceuticals, Inc. logo
Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
June 06, 2013 09:18 ET | Rafarma Pharmaceuticals, Inc.
SANDY, Utah, June 6, 2013 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (the "Company") (Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone. Ceftriaxone treats...